Cargando…

Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy—A retrospective analysis

BACKGROUND: Cutaneous leishmaniasis (CL) is a neglected tropical skin disease, caused by Leishmania protozoa. In Pakistan, where CL caused by L. tropica is highly endemic, therapy with pentavalent antimonials is the standard of care, but has significant toxicity when used in systemic therapy, while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kämink, Suzette, Masih, Boota, Ali, Noor, Ullah, Aman, Khan, Syed Juma, Ashraf, Shakil, Pylypenko, Tetyana, Grobusch, Martin P., Fernhout, Jena, den Boer, Margriet, Ritmeijer, Koert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872246/ https://www.ncbi.nlm.nih.gov/pubmed/33507944 http://dx.doi.org/10.1371/journal.pntd.0008988

Ejemplares similares

Failure of an Innovative Low-Cost, Noninvasive Thermotherapy Device for Treating Cutaneous Leishmaniasis Caused by Leishmania tropica in Pakistan
por: Kämink, Suzette, et al.
Publicado: (2019)

The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia – A review and meta-analysis
por: Pijpers, Joyce, et al.
Publicado: (2019)

A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan
por: Kämink, Suzette S., et al.
Publicado: (2017)

Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate
por: REZAEI RIABI, Tahereh, et al.
Publicado: (2013)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
por: Tayyebi, Masoumeh, et al.
Publicado: (2021)

Miltefosine-Induced Apoptotic Cell Death on Leishmania major and L. tropica Strains
por: Khademvatan, Shahram, et al.
Publicado: (2011)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
por: Vincent, Isabel M., et al.
Publicado: (2015)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021)

The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of Leishmania tropica
por: MAHMOUDVAND, Hossein, et al.
Publicado: (2017)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis
por: SOLOMON, Michal, et al.
Publicado: (2022)

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions
por: Regli, Ivo B., et al.
Publicado: (2018)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
por: Fernández, Olga Lucía, et al.
Publicado: (2014)

Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility
por: Santi, Ana Maria Murta, et al.
Publicado: (2021)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Overexpression of Ubiquitin and Amino Acid Permease Genes in Association with Antimony Resistance in Leishmania tropica Field Isolates
por: Kazemi-Rad, Elham, et al.
Publicado: (2013)

Drug-Resistant Leishmania tropica Parasites Detected in Iranian Cutaneous Leishmaniasis
Publicado: (2006)

Leishmaniasis in Northern Morocco: Predominance of Leishmania infantum Compared to Leishmania tropica
por: Hakkour, Maryam, et al.
Publicado: (2019)

Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
por: van Griensven, Johan, et al.
Publicado: (2014)

Correction: Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Publicado: (2014)

The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018
por: Naylor-Leyland, Gabriel, et al.
Publicado: (2022)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia
por: Boodman, Carl, et al.
Publicado: (2023)

Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jpptd6nr7mfqgdol6ga3911ctv